This invention comprises 11-deoxy-17-phenyl-18,19,20-trinor-prostaglandin-type compounds which exhibit prostaglandin-type pharmacological activity, such as lowering blood pressure, inhibiting gastric secretion, regulating the reproductive cycle, and the like.
|
1. A compound of the formula ##STR1## or a mixture comprising that compound and the enantiomer thereof; WHEREIN G IS 3 TO 5, INCLUSIVE;
Wherein r1 is hydrogen, alkyl of one to 12 carbon atoms, inclusive, cycloalkyl of 3 to 10 carbon atoms, inclusive, aralkyl of 7 to 12 carbon atoms, inclusive, phenyl, phenyl substituted with one or two alkyl of one to 3 carbon atoms, inclusive, or chloro, or a pharmacologically acceptable cation; Wherein L1 is ##STR2## or a mixture of ##STR3## wherein r3 and r4 are hydrogen or methyl, being the same or different; Wherein M1 is ##STR4## wherein r5 and r6 are hydrogen or methyl, with the proviso that r5 is methyl only when r6 is hydrogen and r6 is methyl only when r5 is hydrogen; Wherein r21, r22, r23, r24, and r25 are hydrogen, fluoro, chloro, trifluoromethyl, alkyl of one to 4 carbon atoms, inclusive, or --OR8 wherein r8 is alkyl of one to 3 carbon atoms, inclusive, with the proviso that at least two of r21, r22, r23, r24, and r25 are hydrogen, and not more than two of r21, r22, r23, r24, and r25 are chloro, fluoro, trifluoromethyl or --OR8. 4. A compound according to
7. A compound according to
8. 2a,2b-Dihomo-11-deoxy-17-(m-chlorophenyl)-18,19,20-trinor-13,1
4-dihydro-PGE2, methyl ester, a compound according to
9. 2a,2b-Dihomo-11-deoxy-17-phenyl-18,19,20-trinor-13,14-dihydro-PGE2, methyl ester, a compound according to
10. 2a,2b-Dihomo-11-deoxy-17-(m-trifluoromethyl
phenyl)-18,19,20-trinor-13,14-dihydro-PGE2, methyl ester, a compound according to
12. A compound according to
19. 11-Deoxy-17-(m-chlorophenyl)-18,19,20-trinor-13,14-dihydro-PGE2, a compound according to
21. 11-Deoxy-17-(m-trif
luoromethylphenyl)-18,19,20-trinor-13,14-dihydro-PGE2, a compound according to
|
|||||||||||||||||
The present application is a divisional application of Ser. No. 542,372, filed Jan. 20, 1975, now issued as U.S. Pat. No. 4,029,693, on June 14, 1977.
The present invention relates to prostaglandin analogs for which the essential material constituting a disclosure therefor is incorporated by reference here from U.S. Pat. No. 4,029,693, issued June 14, 1977.
Bundy, Gordon L., Nelson, Norman A.
| Patent | Priority | Assignee | Title |
| Patent | Priority | Assignee | Title |
| 3971826, | Jul 13 1972 | Pfizer Inc. | 15-Substituted-ω-pentanorprostaglandins |
| NL7301094, |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Feb 28 1977 | The Upjohn Company | (assignment on the face of the patent) | / |
| Date | Maintenance Fee Events |
| Date | Maintenance Schedule |
| Apr 24 1982 | 4 years fee payment window open |
| Oct 24 1982 | 6 months grace period start (w surcharge) |
| Apr 24 1983 | patent expiry (for year 4) |
| Apr 24 1985 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Apr 24 1986 | 8 years fee payment window open |
| Oct 24 1986 | 6 months grace period start (w surcharge) |
| Apr 24 1987 | patent expiry (for year 8) |
| Apr 24 1989 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Apr 24 1990 | 12 years fee payment window open |
| Oct 24 1990 | 6 months grace period start (w surcharge) |
| Apr 24 1991 | patent expiry (for year 12) |
| Apr 24 1993 | 2 years to revive unintentionally abandoned end. (for year 12) |